During the past decade, University of Toledo Medical Center conducted 42 clinical trials. In the 10-year time frame, 42 clinical trials started and 25 clinical trials were completed, i.e. on average, 59.5% percent of trials that started reached the finish line to date. In the past 5 years, 16 clinical trials started and 15 clinical trials were completed. i.e. 93.8% of trials that started reached the finish line.

Out of the total clinical trials conducted in "University of Toledo Medical Center" #1 sponsor was "Boston Scientific Corporation" with 6 trials, followed by "University of Toledo Health Science Campus" with 6 trials sponsored, "C. R. Bard" with 2 trials sponsored, "Celgene" with 2 trials sponsored and "Eli Lilly and Company" with 2 trials sponsored. Other sponsors include 47 different institutions and companies that sponsored additional 53 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "University of Toledo Medical Center" #1 collaborator was "National Heart, Lung, and Blood Institute (NHLBI)" with 3 trials as a collaborator, "ARMO BioSciences" with 2 trials as a collaborator, "Massachusetts General Hospital" with 2 trials as a collaborator, "Medical University of South Carolina" with 2 trials as a collaborator and "Merck Sharp & Dohme LLC" with 2 trials as a collaborator. Other collaborators include 48 different institutions and companies that were collaborators in the rest 56 trials.

According to Clinical.Site data, the most researched conditions in "University of Toledo Medical Center" are "Chronic Pain" (3 trials), "Peripheral Arterial Disease" (3 trials), "Pulmonary Arterial Hypertension" (3 trials), "Advanced Solid Tumor" (2 trials) and "Constipation" (2 trials). Many other conditions were trialed in "University of Toledo Medical Center" in a lesser frequency.

Most popular intervention types in "University of Toledo Medical Center" are "Drug" (33 trials), "Device" (23 trials), "Other" (10 trials), "Biological" (7 trials) and "Procedure" (4 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (11 trials), "Pembrolizumab" (3 trials), "Active Investigational Treatment ENT-01" (2 trials), "Dexamethasone" (2 trials) and "Pegilodecakin" (2 trials). Other intervention names were less common.

The vast majority of trials in "University of Toledo Medical Center" are 68 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "University of Toledo Medical Center". 1 are not yet recruiting, 11 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 28 completed trials in University of Toledo Medical Center, undefined suspended trials, and 20 terminated clinical trials to date.

Out of the total trials that were conducted in University of Toledo Medical Center, 6 "Phase 1" clinical trials were conducted, 17 "Phase 2" clinical trials and 19 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 19 trials that are defined as “Not Applicable".